Replies to post #17228 on Ariad Pharmaceuticals Inc fka ARIA

[biomaven0]

She may be wrong on this matter, but McMinn has one of the best track records overall of any biotech sell-side analyst.

Well I'd like to understand what she saw in the briefing documents that made her change her view - these were among the most innocuous briefing documents I've seen - basically no new information of consequence that I saw. A minor change in PFS in both arms by the FDA (that barely changed the delta) and the obvious question by the FDA on the risk/benefit of the drug.

In other words, if she was surprised by something, it could presumably only be because she hadn't studied the information previously provided by the company.

I predict a luke-warm endorsement by the AC followed by approval by the FDA. Commercial prospects remain uncertain, awaiting the results of some combination trials.

Peter